Let’s say you’re a publicly traded manufacturer of a popular medical device, which you sell commercially as well as to a number of VA hospitals. You receive an anonymous internal hotline complaint alleging that certain unauthorized, reverse-engineered components were used in the manufacturing process and that certain quality tests were skipped in the interest of “efficiency.” You triage the complaint, do your preliminary diligence, determine the complaint isn’t frivolous, and launch a privileged internal investigation.

You know you have a legal obligation to investigate (remember, our device manufacturer is a publicly traded federal contractor), but you’re obviously apprehensive about what you might find. You’re also apprehensive about where those findings may take you. You can see the dominoes falling one by one in your mind’s eye.

Click here to read more.

Photo of Jonathan Aronie Jonathan Aronie

Jonathan Aronie is the Leader of the firm’s Governmental Practice Group and is a former Managing Partner of the Washington, D.C. office. Jonathan also is a founding member of the firm’s Organizational Integrity Group, a cross-disciplinary team of litigators, regulatory specialists, federal monitors…

Jonathan Aronie is the Leader of the firm’s Governmental Practice Group and is a former Managing Partner of the Washington, D.C. office. Jonathan also is a founding member of the firm’s Organizational Integrity Group, a cross-disciplinary team of litigators, regulatory specialists, federal monitors, and ex-prosecutors with extensive experience helping organizations prevent and defend against challenges to their organizational integrity.